Western University

Scholarship@Western
Anatomy and Cell Biology Publications

Anatomy and Cell Biology Department

12-1-2018

Survival of patients with subglottic squamous cell carcinoma
S D. MacNeil
Western University

K Patel
Western University

K Liu
Institute for Clinical Evaluative Sciences

S Shariff
Institute for Clinical Evaluative Sciences

J Yoo
Western University

See next page for additional authors

Follow this and additional works at: https://ir.lib.uwo.ca/anatomypub
Part of the Anatomy Commons, and the Cell and Developmental Biology Commons

Citation of this paper:
MacNeil, S D.; Patel, K; Liu, K; Shariff, S; Yoo, J; Nichols, A; Fung, K; and Garg, A X, "Survival of patients with
subglottic squamous cell carcinoma" (2018). Anatomy and Cell Biology Publications. 320.
https://ir.lib.uwo.ca/anatomypub/320

Authors
S D. MacNeil, K Patel, K Liu, S Shariff, J Yoo, A Nichols, K Fung, and A X Garg

This article is available at Scholarship@Western: https://ir.lib.uwo.ca/anatomypub/320

SURVIVAL IN SUBGLOTTIC
CANCER, MacNeil
et al.
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ARTICLE

Survival of patients with subglottic
squamous cell carcinoma
S.D. MacNeil md msc,*† K. Patel md,* K. Liu,† S. Shariff phd,† J. Yoo md,* A. Nichols md,* K. Fung md,*
and A.X. Garg md phd†‡§

ABSTRACT
Objective Subglottic squamous cell carcinoma is a rare subsite of laryngeal cancer that behaves more aggressively
and portends a worse prognosis. Using a population-based cancer registry, our objective was to report overall survival
(os) and laryngectomy-free survival (lfs) in patients diagnosed with subglottic squamous cell carcinoma, and to
determine whether primary laryngectomy results in improved survival.
Methods

This retrospective population-based study considered patients with a new diagnosis of squamous cell
carcinoma in the province of Ontario over a 15-year period (1995–2009). The Ontario Cancer Registry was examined
for patients with the diagnosis of interest during the period of interest. Linked population-based databases were used
to obtain patient demographics, comorbidity measures, staging, survival, and primary treatment with laryngectomy.

Results Of 4927 patients identified to have laryngeal carcinoma, 89 were defined as having primary subglottic
carcinoma (1.8%). In the subglottic cohort, 68 patients were men (76.4%), and mean age at diagnosis was 68 years
(interquartile range: 60–77 years). The 5-year os was 47.2%, and the 5-year lfs was 31.5%. In 13 patients (15%), the
primary treatment was laryngectomy, which, compared with primary radiation, did not predict for improved os. No
differences in os or lfs were observed during the 15-year study period (os p = 0.42, lfs p = 0.83).

Conclusions The survival of patients with subglottic carcinoma is poor and has remained stable over time (1995–
2009). Compared with primary radiation, primary treatment with laryngectomy does not appear to improve os.

Key Words Head-and-neck cancer, larynx, radiation therapy, outcomes
Curr Oncol. 2018 Dec;25(6):e569-e575

INTRODUCTION
Squamous cell carcinoma (scc) of the subglottis is rare,
representing less than 5% of all laryngeal cancer1,2. In the
past, separating primary subglottic cancer from glottic
cancer with subglottic extension was challenging because
of poor imaging and laryngoscopy equipment 3. The superior anatomic boundary of the subglottis has also been
inconsistently defined, ranging from 5 mm to 1 cm below
the lateral margin of the ventricle, further complicating accurate classification of this disease subsite4. The rarity of the
disease, the historic difficulty in separating primary from
secondary subglottic cancer, and the changing definition of
the superior boundary have made it challenging to report
treatment and survival outcomes for this rare carcinoma.

www.current-oncology.com

Secondary to advanced stage at presentation, propensity for paratracheal and upper mediastinal lymphatic
spread, and increased risk of stomal recurrence, primary
subglottic scc is thought to herald a prognosis worse than
that for other subsites of laryngeal cancer5–9. Historically,
total laryngectomy has been the standard of care for the
treatment of subglottic carcinoma 3. More recent retrospective studies have demonstrated comparable survival
outcomes for patients treated with primary radiotherapy2,10–12. However, those studies are limited by institutional selection bias, incomplete surgical data, and lack
of laryngectomy-free survival (lfs) as an outcome2,10–12.
Whether radiation is equivalent to primary laryngectomy
as a treatment option remains unknown. Similarly, there
is no evidence to suggest that the apparent increased use
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of radiotherapy over time has resulted in an improvement
in lfs in this patient population.
The purpose of the present study was to report overall survival (os) and lfs outcomes for patients diagnosed
with subglottic scc in Ontario over a 15-year period and
to determine whether primary laryngectomy results in an
improved os.

METHODS
Study Design and Setting

Residents of Ontario (2014 population estimate: 13, 678,700)13
have universal access to hospital care and physician
services. Those encounters are recorded in large population-based health care databases, many of which are
held at the Institute for Clinical Evaluative Sciences. We
conducted a population-based retrospective cohort study
of all patients with laryngeal carcinoma. The study was
approved by the Sunnybrook Health Sciences Centre research ethics board.

Data Sources
We used five linked databases: the Ontario Cancer Registry,
which records data for all patients with non-skin cancers
diagnosed in Ontario (mandatory reporting)14,15 ; the Discharge Abstract Database held by the Canadian Institute
for Health Information, which records all admissions to
hospitals and includes information about diagnoses and
procedures performed; the ohip (Ontario Health Insurance
Plan) database, which contains information about all feefor-service physician claims for inpatient and outpatient
services; the Registered Persons Database, which contains
vital statistics about all permanent residents of Ontario;
and the National Ambulatory Care Reporting System Database, which collects data about ambulatory care visits,
including day surgery, outpatient clinics, cancer clinics,
and emergency department visits. The databases were
linked using unique encoded identifiers (encrypted Ontario health care numbers that are unique to each resident
eligible for health care services paid by the government)
available starting July 1991, after the assignment of new
health care numbers in Ontario.
We previously used those data sources to study secular trends in other conditions16,17. For the present work,
we used the Ontario Cancer Registry to identify laryngeal
cancer patients (subsite subglottis), and the Discharge
Abstract Database, National Ambulatory Care Reporting
System, ohip database, and Registered Persons Database
to define patient characteristics, baseline comorbidities,
and patient outcomes. Diagnoses were identified using
the codes defined by the International Classification of
Diseases, 9th revision (pre-2002), and 10th revision (post2002). Procedures were identified using the codes defined
in the Canadian Classification of Diagnostic, Therapeutic,
and Surgical Procedures (pre-2002) and the Canadian
Classification of Health Interventions (post-2002).

Patients
All patients with a diagnosis of laryngeal cancer and scc on
histology during 1995–2009 in the province of Ontario were
retrospectively reviewed. To allow for a complete 3-year
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look-back for baseline comorbidities, cohort accrual began
1 January 1995. We restricted the cohort to patients who were
residents of Ontario and who had a histologic diagnosis of
scc. A prior validation study found a sensitivity of 89.8% and
a positive predictive value of 96.8% for the diagnostic code
for laryngeal cancer in the registry compared with a clinical
database18. The date of the laryngeal cancer diagnosis (“index date”) served as the start time for follow-up.
Patients were further divided into groups for supraglottic, glottic, and subglottic cancers. Staging data were
available only for the subpopulation diagnosed from 2005
to 2009. Registry staging ranged from i to iv and was derived
from the American Joint Committee on Cancer staging
manual (6th or 7th edition)4. We classified patients with
stage I or ii disease as “early stage.” According to both
versions of the staging manual, the early-stage grouping
included patients with local disease only and excluded
patients with regional or distant metastases. Patients with
stage iii or iv disease were classified as “advanced stage.”
That group included patients with advanced local disease
and patients with regional or distant metastasis. Patients
who underwent laryngectomy within 3 months of the initial
diagnosis were considered to be have been treated with
primary laryngectomy. We assumed that 3 months would
allow enough time to capture patients whose treatment was
delayed for other medical problems, but would be too soon
for radiation failure to be identified (assuming 6- to 7-week
course of radiation). Patients who underwent laryngectomy
after 3 months were considered to have experienced radiotherapy failure requiring a salvage laryngectomy. Those not
treated with primary laryngectomy were assumed to have
been treated with primary radiation.

Outcomes
We categorized the study period into three eras: 1995–1999,
2000–2004, and 2005–2009. We selected those eras to correspond to the availability of staging data, which began in
2004. Thus, the cohort was allocated into 3 approximately
equal periods. We determined 5-year mortality after a
subglottic cancer diagnosis for each of the 3 eras and the
rate per 100 person–years. We assessed 2 primary outcomes
in the 5 years after a new diagnosis of laryngeal cancer: os
and lfs. We defined os as the proportion of patients alive
at 5 years from the date of diagnosis, censoring for patients
who were lost to follow-up before 5 years. We defined lfs as
the proportion of patients alive at 5 years from the date of
diagnosis with an intact larynx, censoring for patients who
were lost to follow-up. Deaths (including out-of-hospital
mortality) are well ascertained in the Registered Persons
Database, which provides accurate mortality data for all
Ontario residents19.

Statistical Analysis
For each of the defined eras and for the 15-year overall
period, mean age with standard deviation, age group (≤64
years, ≥65 years), sex, Charlson comorbidity group (0, 1,
≥2), and treatment (laryngectomy, salvage laryngectomy, radiation) are reported. To determine whether the
demographic characteristics of the patients differed in
each era, the Kruskal–Wallis test for continuous variables
was applied.
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We determined the crude 5-year mortality for patients
after a subglottic cancer diagnosis and calculated the rate
per 100 person–years. Kaplan–Meier plots adjusting for age
group, Charlson comorbidity group, and sex (male/female)
were generated for both 5-year os and 5-year lfs.
For the patients in each of the 3 eras, Kaplan–Meier
plots were generated for both 5-year os and 5-year lfs. We
used the log-rank test to determine whether a difference
was evident between the 3 eras for each survival outcome.
We used the PHREG procedure in the SAS software
application (version 9.3: SAS Institute, Cary, NC, U.S.A.)
to create a Cox proportional hazards regression model
investigating the association between treatment with
surgery or radiation and survival, adjusting for the influence of potential confounders (age, sex, and Charlson
comorbidity group).
SAS was used for all statistical analyses. We interpreted
2-tailed p values less than 0.05 as statistically significant.

RESULTS
Cohort Description and Demographics
From 1995 to 2009, 4977 patients in Ontario were diagnosed
with laryngeal cancer. Of that group, 50 patients were
excluded because of insufficient information, leaving
4927 patients, 1371 of whom (27.83%) were diagnosed
supraglottic cancer; 3201 (64.97%), with glottic cancer; and
89 (1.81%), with subglottic cancer (Figure 1).
Of the 89 patients with subglottic cancer, 31 were
diagnosed during 1995–1999, 31 during 2000–2004, and
27 during 2005–2009. Table i reports the baseline characteristics of those patients. Mean age at diagnosis was 68
years, and 68 of the patients were men (76.4%). Primary
laryngectomy was used to treat 13 patients (14.6%); 15
patients (16.9%) underwent salvage laryngectomy; and 61

patients (68.5%) did not undergo laryngectomy within 5
years of diagnosis. The number of patients who underwent
laryngectomy did not differ in the 3 eras (p = 0.23).

Five-Year Survival Trends
Table ii outlines the 5-year mortality after a diagnosis of
subglottic cancer. The 5-year mortality was 58.06% (18/31)
during 1995–1999, 41.94% (13/31) during 2000–2004, and
59.26% (16/27) during 2005–2009. Mortality rates were not
significantly different in the 3 diagnosis eras (p = 0.42). For
the cohort overall, the 5-year os was 47.2%, and the 5–year
lfs was 31.5% (Figures 2 and 3).

Survival Analysis
Results of the survival analysis indicate that age (≥65 years
vs. ≤64 years) is a significant predictor of 5-year mortality
(hazard ratio: 2.57; 95% confidence interval: 1.25 to 5.26;
Table iii). No significant difference in 5-year mortality was
observed for patients treated with primary laryngectomy
compared with those treated with primary radiation
(hazard ratio: 1.21; 95% confidence interval: 0.55 to 2.67).

DISCUSSION
In the Canadian province of Ontario, subglottic scc represented 1.8% of all new diagnoses of laryngeal cancer during
1995–2009. The 5-year os for the subglottic site was 47.2%
compared with 57.4% for the other laryngeal subsites16.
During the 15-year period of interest, we observed no
improvement in os or lfs. Furthermore, we found no difference in survival between patients treated with primary
laryngectomy and those treated with primary radiotherapy.
TABLE I Baseline characteristics of 89 patients in Ontario with
subglottic squamous cell cancer, 1995–2009
Variable
Mean age (years)

Value
68.0±11.1

Age group [n (%)]
<65 Years

32 (35.9)

≥65

57 (64.0)

Sex [n (%) men]

68 (76.4)

Stagea (n)
I/II

12

III/IV

≤15

Treatment [n (%)]
Primary laryngectomyb

13 (14.6)

Radiationc

61 (68.5)

Salvage

laryngectomyd

15 (16.9)

a

Staging information was available only for 2005–2009.
as patients undergoing laryngectomy within 3 months of
the date of diagnosis.
c	
Radiation codes were unavailable. We therefore assumed that, if
patients did not undergo primary laryngectomy, they had been
treated with radiation. However, patients who received no treatment
might also have been included in this group.
d	Defined as patients undergoing laryngectomy more than 3 months
after the date of diagnosis.
b	Defined

FIGURE 1 Selection of patients for the subglottic cancer cohort.
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TABLE II Five-year mortality after a diagnosis of subglottic cancer
Diagnosis
period

Patients
(n)

5-Year mortality
[n (%)]

Deaths per
100 person–years

1995–1999

31

18 (58.1)

19

2000–2004

31

13 (41.9)

12

2005–2009

27

16 (59.3)

20

TABLE III Mortality at 5 years after a diagnosis of subglottic squamous
cell carcinoma
Variable

Adjusted HR

95% CI

Age group
<65
≥65
FIGURE 2
survival.

Kaplan–Meier plot depicting 5-year laryngectomy-free

1.0 (Reference)
2.57

1.25 to 5.26

Sex
Women
Men

1.0 (Reference)
1.26

0.62 to 2.56

CCI group
0

1.0 (Reference)

1

1.09

0.32 to 3.67

≥2

1.97

0.86 to 4.50

Treatment group
Radiation
Primary laryngectomy

1.0 (Reference)
1.21

0.55 to 2.67

HR = hazard ratio; CI = confidence interval; CCI = Charlson comorbidity
index.

FIGURE 3 Kaplan–Meier plot depicting 5-year overall survival.

staging information before 2005 probably accounts for
the variability in stage presentation. The largest reported
study of patients with subglottic scc demonstrated a 58.4%
(219/375) rate of advanced-stage presentation11. Taken
together, those data indicate that patients are slightly
more likely to present with advanced-stage than with earlystage disease.

Subglottic Carcinoma Characteristics

Subglottic Carcinoma Treatment

The demographic characteristics of the study patients
are consistent with those reported in other studies,
demonstrating the face validity of the present work1,5,16,20.
Subglottic carcinoma in our cohort represented 1.8% of
all laryngeal sccs. Other studies have found incidence
rates in the range of 1.0% –8.7% for subglottic laryngeal
scc, although most studies report a range 1%–1.6% 5,20,21.
Variability in the definition of primary subglottic scc over
time and the inclusion of cancers of other histology in
the definition of subglottic scc is the likely reason for the
discrepancy in the incidence reported here compared with
other series10,21–23.
Primary subglottic carcinoma is usually asymptomatic
early in the disease process and is traditionally thought to
present at an advanced stage (50%–64% of patients)2,5,8,11.
However, we found an even distribution between patients
presenting with early-stage and advanced-stage disease.
The small number of patients in our series and lack of

The treatment options for primary subglottic carcinoma
include surgery (laryngectomy or partial laryngectomy),
radiation (with or without chemotherapy), or combination
therapy. Direct extra-laryngeal extension, a circumferential pattern of intraluminal spread and cartilage invasion,
means that few patients are candidates for partial laryngectomy as primary treatment 24. With a few exceptions
(patients undergoing partial or hemi-laryngectomy), most
patients in other studies underwent total laryngectomy
(Table iv). Other studies showed significant variability
with respect to primary treatment administered (Table iv).
In some studies, patients were treated with primary surgery1,11,25,27; in others, most patients were treated with primary radiotherapy10,12,20,26,28. Furthermore, the indications
for combined-modality treatment, adjuvant radiation, and
salvage laryngectomy were often not reported.
In our study, 13 patients (14.6%) underwent primary
laryngectomy. Other reports in the literature describe
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TABLE IV Subglottic carcinoma treatment and survival outcomes in the literature
Reference

Vermund,

19703,a

Patients
(n)

Stage
Group

185

Shaha and Shah, 198225

16

Warde et al., 198726

23

Guedea et al., 199112

6

Haylock and Deutsch, 199320

23

Dahm et al., 199822

28

Strome et al., 19992

10d

Santoro et al., 200027

49

Paisley et al., 200210

Treatment
(n)

NR
I/II
III/IV
I/II
III/IV
I/II
III/IV
I/II
III/IV
I/II
III/IV

3
13
9
14
3
3
13
10
19
9

I/II
III/IV
I/II
III/IV

5
4
17
32

43

I/II
III/IV

23
20

Garas and McGuirt, 20061

15

I/II
III/IV

3
12

Smee et al., 20085

10

I/II
III/IV

6
4

Hata et al., 201328

19

Marchiano et al., 201611

889

I/II
III/IV
I/II
III/IV

9
10
126
219

Present study

89

I/II
III/IV

12
12

Protocol

(n)

TLa

58
127
13
3
22
1
4
2
21
2
10
1
2
2
10
2
1
3
6
17
18
6
8
29
13
1
3
6
4
2
1
4
1
4
5
14
139
277
317
85
71
13
76

RT
TL
PL
RT
RT with sTL
RT
RT with sTL
RT
RT with sTL
TL
TL with aRT
PL
PL with aRT
RT
RT with salvage Sx
Palliation
TL with aRT
RT
TL
TL with aRT
RT
Palliation
RT
RT with sTL
CRT
TL
TL with aRT
RT
RT with sTL
TL
TL with aRT
PL with aRT
RT
RT
CRT
Sxh
RT
Sxh with RT
Palliation
Unknown
TL
RT

OS
(5-year %)
42
36
70
26
33
(4-year %)
58
58c

67
56e

50

25f

70

80g
41.5

47

a	Literature

review, including 20 studies. Some patients received adjuvant treatment.
difference in survival between treatment groups. The 5-year overall survival was 44% for RT alone, 50% for surgery alone, and 100% for
combined therapy.
d
Staging was unavailable for 1 patient.
e	The 5-year overall survival for patients treated with RT alone, with TL alone, or with TL and aRT was 0%, 47%, and 83.3% respectively. Survival
was statistically significantly different for patients receiving TL with aRT compared with those receiving TL alone or RT alone (p = 0.001).
f	The 3-year overall survival was 0% for patients treated with TL, 40% for those treated with TL and aRT, 33.3% for those treated with RT, and 0%
for those treated with RT and sTL.
g	The 5-year overall survival was 100% for patients treated with CRT and 92% for those treated with RT.
h	Population-based study using U.S. Surveillance, Epidemiology, and End Results data that provided no further detail about the extent of surgery.
OS = overall survival; NR = not reported; TL = total laryngectomy; RT = radiation therapy; PL = partial laryngectomy; sTL = salvage total laryngectomy;
aRT = adjuvant radiation therapy; Sx = undefined surgery; CRT = chemoradiation therapy.
c	No
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31% –81% of patients being treated with primary total
laryngectomy and 10% –30% of patients being treated
with partial laryngectomy1–3,5. We were not able to determine whether any patients in our cohort underwent
partial laryngeal surgery. In our cohort, 68.5% of patients
were managed non-surgically. Other studies reported
12%–100% of patients being treated with primary radiotherapy1–3,5,10,12,20,28. We did not have access to radiation
or chemotherapy billing codes, and we therefore assumed
that, if patients did not receive primary laryngectomy, they
were treated with radiation. However, some of the latter
patients could have been treated with palliative intent.
Our reported rate of salvage laryngectomy was 16.9%, but
that number might have been larger, because some of the
patients in the denominator might have been palliated.
Data from our study and others do not make clear what proportion of patients treated with primary radiation required
salvage laryngectomy and whether organ-preservation
protocols improve lfs.

Survival Outcomes
We report a 5-year os of 47.2% for the overall group of patients with a diagnosis of subglottic scc. Previous studies
have reported 5-year os rates ranging from 25% to 80%
(Table iv). Some authors have suggested that a higher rate
of local recurrence, particularly at the peristomal region,
or a high rate of distant metastatic spread up to 32% is
responsible for the poor os; however, the data are unclear22. Earlier studies (Table iv) suggest that combinedmoda lit y treatment— eit her surger y plus radiation,
chemotherapy plus radiation, or radiation followed by
salvage surgery—offers a survival benefit. However, small
sample sizes prevent definitive conclusions from being
drawn 2,5,28. Limitations in our databases meant that we
were unable to determine whether patients in our cohort
received combined-modality treatment. Our results do,
however, suggest that primary laryngectomy might not
provide a survival benefit.
We observed no change in os or lfs from 1995 to
2009 (Figures 1 and 2). Those results are consistent with
prior work by our group and others demonstrating no
change in os in patients with glottic and supraglottic
carcinomas16,29–31. Although large randomized trials have
demonstrated an improved lfs for patients with glottic
and supraglottic carcinoma treated with concurrent
chemoradiation, that benefit has not been demonstrated
in population-based studies16,29,30. The reasons for the
discrepancy are unknown, but could be related to patient
selection for laryngeal-preservation protocols. Additionally, the difficulty in differentiating primary subglottic
carcinoma from glottic carcinoma with subglottic extension and the evolving definition of the superior boundary
of the subglottis could have influenced survival trends
over the study period.

Strengths and Limitations
To our knowledge, the present study is the largest reported in the literature assessing the outcome of lfs in
patients with subglottic carcinoma. Our survival outcome
is robust, accounting for all patients with a diagnosis of
subglottic carcinoma in the province of Ontario. That is,
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no selection bias is inherent in institutional reviews of
survival outcomes. Procedural and diagnostic codes were
well-documented18.
However, our study has limitations. We had only
T stage and N stage information available for 2005–2009,
and thus the stage analysis was limited. Furthermore,
disease-specific survival was not calculated because cause
of death has a low sensitivity in cancer registries and population databases. We assumed that patients who did not
receive a primary laryngectomy were treated with primary
radiation. Some of those patients might have been treated
with palliative intent or might have received no treatment.
Lack of radiation and chemotherapy treatment codes limited the analysis.

CONCLUSIONS
Compared with other laryngeal cancer subsites, subglottic
carcinoma has a low incidence and a poor prognosis. The
reason for poor os in patients with this subsite of laryngeal
cancer is unknown, but appears to have no association with
advanced stage at presentation. Overall, we observed no
difference in the 5-year mortality rate for patients treated
with primary laryngectomy and those treated without
laryngectomy. Thus laryngeal preservation therapy could
be considered a primary option for suitable patients. More
research is needed to determine which patients are suitable
for laryngeal-preservation treatment protocols and which
should receive primary laryngectomy.
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